Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

January 17, 2024 updated by: Scynexis, Inc.

Oral Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis (VVC) in Subjects Who Have Failed Fluconazole Therapy

This study will treat subjects with complicated VVC who have failed prior fluconazole therapy with Ibrexafungerp for 1, 3 or 7 days of treatment.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study will treat subjects with complicated VVC who have failed prior fluconazole therapy with Ibrexafungerp for 1, 3 or 7 days of treatment.

Approximately 150 eligible subjects will be enrolled. Subjects will be randomized to receive oral ibrexafungerp 300 mg administered twice a day (BID) for either one, three, or seven consecutive days, stratified by group based on Candida species and presence or absence of underlying medical conditions.

The primary endpoint for this study is the percentage of subjects with a clinical cure at the Test of Cure Visit. Test of Cure is defined as a score of zero on the Vulvovaginal Signs and Symptoms Scale and not requiring additional antifungal treatment.

Study Type

Interventional

Enrollment (Actual)

150

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Arizona
      • Phoenix, Arizona, United States, 85032
        • Precision Trials, AZ
    • California
      • San Diego, California, United States, 92111
        • Women's Healthcare Research
      • San Diego, California, United States, 92120
        • Wake Research (MCCR)
    • Florida
      • Miami, Florida, United States, 33186
        • New Age Medical Research
    • Georgia
      • Atlanta, Georgia, United States, 30328
        • Wake (Mount Vernon Clinical Research)
    • Idaho
      • Idaho Falls, Idaho, United States, 83404
        • Clinical Research Prime
      • Idaho Falls, Idaho, United States, 83404
        • Leavitt Women's Healthcare
    • Louisiana
      • New Orleans, Louisiana, United States, 70125
        • Women Under Study
    • Massachusetts
      • Boston, Massachusetts, United States, 02114
        • Massachusetts's General
    • Michigan
      • Detroit, Michigan, United States, 48201
        • Wayne State University
    • Missouri
      • Saint Louis, Missouri, United States, 63131
        • Consultants in Women's Healthcare
    • Nevada
      • Las Vegas, Nevada, United States, 89123
        • Wake Research (CRCN)
    • New Jersey
      • Lawrenceville, New Jersey, United States, 08648
        • Capital Health Lawrence OBGYN
    • New York
      • Lake Success, New York, United States, 11042
        • Center for Colposcopy
    • North Carolina
      • Fayetteville, North Carolina, United States, 28303
        • Wake Research (Carolina Institute for Clinical Research)
      • Raleigh, North Carolina, United States, 27607
        • UWCR - Raleigh
      • Winston-Salem, North Carolina, United States, 27103
        • Lyndhurst Clinical Research
    • Ohio
      • Cleveland, Ohio, United States, 44195
        • Cleveland Clinic
    • Oregon
      • Portland, Oregon, United States, 97239
        • Oregon Health and Science University
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
        • Jefferson University
    • Tennessee
      • Memphis, Tennessee, United States, 38120
        • Medical Research Center
    • Texas
      • Dallas, Texas, United States, 75230
        • Discovery Clinical Trials
      • Houston, Texas, United States, 77054
        • TMC Life Research, Inc
      • McAllen, Texas, United States, 78503
        • Discovery Clinical Trials
    • Washington
      • Seattle, Washington, United States, 98105
        • Seattle Clinical Research Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Subject is a post menarchal female ≥18 years of age at the time of signing the ICF.

  2. Subject has a diagnosis of symptomatic VVC that meets the following criteria at the

    Screening visit:

    1. Minimum composite vulvovaginal signs and symptoms score of ≥4 with at least 2 signs or symptoms having a score of 2 (moderate) or greater on the VSS scale at baseline.
    2. Positive microscopic examination with 10% KOH in a vaginal sample collected at Screening revealing yeast forms (hyphae/pseudohyphae) or budding yeasts
    3. Normal vaginal pH (≤ 4.5).
    4. Has no other vaginal co-infections based on wet mount microscopic examination (and/or DNA probe).

  3. Subject should also have:

    1. A VVC with persistent symptoms despite fluconazole therapy (last dose of fluconazole must have been administered at least 7 days prior, but no longer than 28 days prior to screening. OR
    2. A recurrent vulvovaginal candidiasis (RVVC) episode with breakthrough symptoms while receiving maintenance antifungal therapy. OR
    3. A VVC episode caused by a non-albicans candida species known to have either intrinsic resistance to fluconazole e.g. C.krusei or suspected resistance to fluconazole, e.g. C.glabrata, C. auris but likely without MIC data in hand. OR
    4. A VVC episode caused by Candida species with documented resistance to fluconazole based on MIC determination. OR
    5. A known history of azole allergy or intolerance.
  4. Subject is able to take oral tablets.
  5. Subject is not pregnant or lactating and plans not to become pregnant. Women of childbearing potential < 1 year post-menopausal must agree to and comply with using one barrier method (male condom, female condom, and diaphragm) plus one other highly effective method of birth control, or sexual abstinence, from the time of consent through 10 days after the completion of study therapy. Subjects must refrain from using any topical vaginal contraceptives as these may have an impact on the signs and symptoms of VVC. Note: Women of childbearing potential must have a negative urine pregnancy test prior to enrollment (performed by the site's local laboratory).
  6. Subject is able to understand and sign a written ICF, which must be obtained prior to treatment and any study-related procedures.
  7. Subject is able to understand and sign a consent or authorization form, which shall permit the use, disclosure and transfer of the subject's personal health information (e.g., in the US Health Information Portability and Accountability Act Authorization form).
  8. Subject is able to understand and follow all study-related procedures including study drug administration.

Exclusion Criteria:

  1. Subject has any vaginal condition other than VVC that may interfere with the diagnosis or evaluation of response to therapy, such as concurrent causes of vulvovaginitis and/or cervicitis including bacterial vaginosis, Trichomonas, Herpes virus, Neisseria gonorrhoeae, Chlamydia, symptomatic human papillomavirus infection, or other mixed infections.

  2. Subject received systemic and/or topical vaginal antifungal treatment, including prescription or over-the-counter products, within 7 days prior to the Screening visit.

    Note: The screening visit may be rescheduled if required.

  3. Subject is receiving or anticipates requiring treatment with the prohibited medications within the specified timeframes per Appendix I.
  4. Subject has active menstruation at the Screening visit. Note: The Screening visit may be rescheduled if required.
  5. Subject has a history of or an active cervical/vaginal cancer.
  6. Subject has a known hypersensitivity to any of the components of the formulation.
  7. Subject has participated in any other investigational study within at least 30 days (or 5.5 half- lives of the investigational product) before signing the ICF.
  8. Subject has received prior treatment with ibrexafungerp.
  9. Subject has any other condition or laboratory abnormality (such as severe hepatic impairment) that, in the judgment of the investigator, would put the subject at unacceptable risk for participation in the study or may interfere with the assessments included in the study.
  10. Subject is unlikely to comply with protocol requirements.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group A
Single day dosing, 300mg Ibrexafungerp BID for a total of 600mg a day.
Drug: Ibrexafungerp
Each day dosing will consist of two 150mg tablets taken BID.
Experimental: Group B (3 Day dosing)
Three day dosing, 300 mg Ibrexafungerp BID for a total of 600mg a day.
Drug: Ibrexafungerp
Each day dosing will consist of two 150mg tablets taken BID.
Experimental: Group b (7 Day dosing)
Seven day dosing, 300mg Ibrexafungerp BID for a total of 600mg a day
Drug: Ibrexafungerp
Each day dosing will consist of two 150mg tablets taken BID.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical Cure
Time Frame: 14 Days post Baseline
Measured by the percentage of subjects with clinical cure (total composite score of 0 on the Vulvovaginal Signs and Symptoms [VSS] Scale with no additional antifungal therapy required based on investigator's judgment) at the Test-of-Cure (TOC) visit. The VSS Scale measures 3 signs and 3 symptoms of VVC, each on a scale of 0 (none) to 3 (severe). The minimum score for the VSS is 0 and the maximum is 18, with higher scores indicating more severe disease.
14 Days post Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical Improvement
Time Frame: 14 Days post Baseline through 60 days post End of Treatment
Percentage of subjects with a total composite score of 2 and percentage of subjects with a total composite score of 1 on the VSS scale.
14 Days post Baseline through 60 days post End of Treatment
Clinical Success
Time Frame: 14 Days post Baseline through 60 days post End of Treatment
Percentage of subjects with a 50% reduction from Baseline in total composite VSS score.
14 Days post Baseline through 60 days post End of Treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Scynexis, Inc.

Investigators

  • Study Director: Lori Tierney, Scynexis, Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2022

Primary Completion (Actual)

May 16, 2023

Study Completion (Actual)

August 2, 2023

Study Registration Dates

First Submitted

May 23, 2022

First Submitted That Met QC Criteria

May 26, 2022

First Posted (Actual)

June 1, 2022

Study Record Updates

Last Update Posted (Actual)

January 18, 2024

Last Update Submitted That Met QC Criteria

January 17, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SCY-078-307b

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vulvovaginal Candidiasis

Clinical Trials on Ibrexafungerp

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe